{"product_id":"precision-cancer-therapies-immunologic-approaches-for-the-treatment-of-lymphoid-malignancies-isbn-9781119824541","title":"Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies","description":"\u003cp\u003e\u003cb\u003ePresents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eThe \u003ci\u003ePrecision Cancer Therapies\u003c\/i\u003e series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science\u003cb\u003e. \u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003ePrecision Cancer Therapies, Volume Two, \u003c\/i\u003efocuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). \u003c\/p\u003e\u003cp\u003eDivided into nine sections, \u003ci\u003eVolume Two\u003c\/i\u003e includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug\/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: \u003c\/p\u003e\u003cul\u003e \u003cli\u003eDelivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology\u003c\/li\u003e \u003cli\u003eFocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms\u003c\/li\u003e \u003cli\u003eCovers FDA-approved drugs and their indications, as well as drugs currently in development\u003c\/li\u003e \u003cli\u003eProvides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy\u003c\/li\u003e \u003cli\u003eIncludes boxed sections highlighting major unique points about the information in the chapter \u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003ci\u003ePrecision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice \u003c\/i\u003eis an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject. \u003c\/p\u003e\u003cp\u003eList of Contributors xix\u003c\/p\u003e \u003cp\u003eVolume Foreword xxiv\u003c\/p\u003e \u003cp\u003eVolume Preface xxvi\u003c\/p\u003e \u003cp\u003eSeries Preface xxviii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I Historical Perspective 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 The Distinguished History of Immunotherapy Development in Cancer 3\u003cbr\u003e\u003ci\u003eStephen M. Ansell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II Targeting Cell Surface Receptors 9\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11\u003cbr\u003e\u003ci\u003eGeorge J. Weiner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22\u003cbr\u003e\u003ci\u003eJennifer K. Lue and Bruce D. Cheson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Pharmacology to Practice: Targeting CD19 and 22 40\u003cbr\u003e\u003ci\u003eNilanjan Ghosh and Sonali M. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52\u003cbr\u003e\u003ci\u003eMichael Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III Antibody Drug Conjugates (ADC) 73\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6 Principles of Antibody Drug Development 75\u003cbr\u003e\u003ci\u003eEric L. Sievers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Targeting CD30 in Lymphoid Neoplasms 87\u003cbr\u003e\u003ci\u003eBarbara Pro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Targeting CD79b in B-cell Malignancies 100\u003cbr\u003e\u003ci\u003eColette Owens and Gilles Salles\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Radioimmunotherapy: Is There Any Future Role? 108\u003cbr\u003e\u003ci\u003eAlessandro Broccoli and Pier Luigi Zinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV Targeting Immune Checkpoint 123\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 The Biology of Immune Checkpoint Blockade 125\u003cbr\u003e\u003ci\u003eTimothy N. Bullock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1\/PDL-1 and CTLA-4 139\u003cbr\u003e\u003ci\u003eMarc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Other Immune Checkpoint Targets of Interest 156\u003cbr\u003e\u003ci\u003eClifford M. Csizmar and Stephen M. Ansell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190\u003cbr\u003e\u003ci\u003eJohn M. Timmerman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V Targeting Macrophages and SIRP-α – Disrupting the \"Do Not Eat Me\" 209\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 211\u003cbr\u003e\u003ci\u003eMithunah Krishnamoorthy, Robert A. Uger, and Mark Wong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Single Agent and Rational Combination Experiences with Anti-CD47 Targeted Drugs 225\u003cbr\u003e\u003ci\u003eNadia Khan, Swathi Namburi, and Krish Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VI EBV Directed Immunotherapies 233\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16 Understanding the Role of EBV Infection in Lymphomagenesis 235\u003cbr\u003e\u003ci\u003eHiroshi Kimura and Takayuki Murata\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies 246\u003cbr\u003e\u003ci\u003eJason Yongsheng CHAN, Seok Jin Kim, Soon Thye LIM, Choon Kiat ONG, and Won Seog Kim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VII Exploiting Tumor Associated Antigens with Autologous T-Cells 257\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 The Scientific Rationale for Targeting Tumor-Associated Antigens 259\u003cbr\u003e\u003ci\u003eJean-Sébastien Delisle and Marie-France Aubin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Clinical Experiences with TAA-T in Lymphoid Malignancies 276\u003cbr\u003e\u003ci\u003eKeri Toner, Hannah Kinoshita, and Catherine M. Bollard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VIII Chimeric Antigen Receptor T-Cells (CAR-T) 289\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20 The Science of CAR-T Cell Technology 291\u003cbr\u003e\u003ci\u003eRichard C. Godby, Allison M. Bock, Saad S. Kenderian, and Yi Lin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 The Spectrum of CAR T Assets in Development: Similarities and Differences 304\u003cbr\u003e\u003ci\u003eJ. Erika Haydu and Jeremy S. Abramson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Clinical Experience with CAR-T Cells for Treatment of B-cell Lymphomas 318\u003cbr\u003e\u003ci\u003eStephen J. Schuster and John G. Gribben\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 \"Off the Shelf\" CAR-T\/NK Cells 341\u003cbr\u003e\u003ci\u003eNancy D. Marin, Alice Zhou, Miriam T. Jacobs, and Todd A. Fehniger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Programming Myeloid Cells with Chimeric Antigen Receptor Myeloid-Based Therapies 360\u003cbr\u003e\u003ci\u003eMiriam Barnett, Michele Gerber, Siddartha Mukherjee, and Daniel Getts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IX Miscellaneous Topics in Immunotherapy 373\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25 Mechanistic Basis and Role of Immunomodulatory Drugs 375\u003cbr\u003e\u003ci\u003eJohn G. Gribben\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Analytical Tools to Quantitate Immune Mediated Effects: What Should We Measure and How? 384\u003cbr\u003e\u003ci\u003eKevin D. Pavelko and Jose C. Villasboas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 The Role of the Microbiome in Immune Response 397\u003cbr\u003e\u003ci\u003eMáire A. Conrad, Kathleen E. Sullivan, and Judith Kelsen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response 406\u003cbr\u003e\u003ci\u003eEnrica Marchi, Ipsita Pal, John Sanil Manvalan, Kallesh Danappa Jayappa, and Owen A. O'Connor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma 429\u003cbr\u003e\u003ci\u003eBruce D. Cheson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eConclusions 433\u003c\/p\u003e \u003cp\u003eMust Reads 433\u003c\/p\u003e \u003cp\u003eReferences 433\u003c\/p\u003e \u003cp\u003eIndex 436\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eOWEN A. O’CONNOR, MD, PhD, \u003c\/b\u003eAmerican Cancer Society Research Professor; Professor of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eSTEPHEN M. ANSELL, MD, PhD, \u003c\/b\u003eConsultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eJOHN G. GRIBBEN, MD, DSc, \u003c\/b\u003eHamilton-Fairley Chair of Medical Oncology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.   \u003c\/p\u003e\u003cp\u003e \u003cb\u003eProvides a definitive, state-of-the-art review of relevant tumor biology and its importance in the broader context of cancer biology\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eOver the past two decades, a better understanding of the biology of lymphoid malignancies has led to the development of many classes of new, highly active drugs that present opportunities to impact the clinical outcome of many patients.  \u003c\/p\u003e\u003cp\u003e\u003ci\u003ePrecision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, \u003c\/i\u003efocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms. This authoritative reference covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).  \u003c\/p\u003e\u003cp\u003eIn-depth chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug\/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. Information on monotherapy and combination therapy, summary tables of trials, discussion of toxicity and efficacy, and boxed sections highlighting major points are integrated throughout the text. \u003c\/p\u003e\u003cp\u003eAuthored and edited by the foremost authorities in the field, \u003ci\u003ePrecision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies \u003c\/i\u003eis an indispensable resource for medical, scientific, and allied medical professionals. \u003c\/p\u003e\u003cp\u003eThe \u003ci\u003e\u003cb\u003ePrecision Cancer Therapies \u003c\/b\u003e\u003c\/i\u003eseries helps professionals understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989839659237,"sku":"NP9781119824541","price":210.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119824541.jpg?v=1761785642","url":"https:\/\/k12savings.com\/products\/precision-cancer-therapies-immunologic-approaches-for-the-treatment-of-lymphoid-malignancies-isbn-9781119824541","provider":"K12savings","version":"1.0","type":"link"}